Innovation was the watchword at CAR-TCR in Boston last month, but one of the limitations of innovation is that it can be challenging for an industry to transition from the rapid iteration s
In an industry growing as quickly as cell therapy, keeping up with the demands of manufacturing and treatment is a challenge for the whole industry to tackle together, including stakeholder
If we learned anything at CAR-TCR it’s that CAR-T therapies are still a relatively new treatment modality and innovation is happening along many different axes.
